EP1415667A4 - Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler - Google Patents

Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler

Info

Publication number: EP1415667A4
Authority: EP; European Patent Office
Prior art keywords: pancreatic juice; juice secretion; lpa receptor; lpa; controller
Prior art date: 2001-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP02746091A

Other languages

English (en)

French (fr)

Other versions

EP1415667B1 (de

EP1415667A1 (de

Inventor

Shinji Nakade

Hiroshi Saga

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ono Pharmaceutical Co Ltd

Original Assignee

Ono Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-17

Filing date

2002-07-16

Publication date

2006-04-19

2002-07-16 Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd

2004-05-06 Publication of EP1415667A1 publication Critical patent/EP1415667A1/de

2006-04-19 Publication of EP1415667A4 publication Critical patent/EP1415667A4/de

2008-09-03 Application granted granted Critical

2008-09-03 Publication of EP1415667B1 publication Critical patent/EP1415667B1/de

2022-07-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000001819 pancreatic juice Anatomy 0.000 title abstract 4
230000028327 secretion Effects 0.000 title abstract 3
102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title abstract 2
108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title abstract 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 3
241000700157 Rattus norvegicus Species 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000001802 infusion Methods 0.000 abstract 1
239000008141 laxative Substances 0.000 abstract 1
230000002475 laxative effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
210000003462 vein Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Non-Alcoholic Beverages (AREA)

EP02746091A 2001-07-17 2002-07-16 Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler Expired - Lifetime EP1415667B1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2001216133		2001-07-17
JP2001216133		2001-07-17
PCT/JP2002/007213 WO2003007991A1 (fr)	2001-07-17	2002-07-16	Regulateurs de la secretion de suc pancreatique comprenant un agent de regulation du recepteur a lpa

Publications (3)

Publication Number	Publication Date
EP1415667A1 EP1415667A1 (de)	2004-05-06
EP1415667A4 true EP1415667A4 (de)	2006-04-19
EP1415667B1 EP1415667B1 (de)	2008-09-03

Family

ID=19050646

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02746091A Expired - Lifetime EP1415667B1 (de)	2001-07-17	2002-07-16	Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler

Country Status (7)

Country	Link
US (2)	US20040171582A1 (de)
EP (1)	EP1415667B1 (de)
JP (1)	JPWO2003007991A1 (de)
AT (1)	ATE406915T1 (de)
DE (1)	DE60228732D1 (de)
ES (1)	ES2312588T3 (de)
WO (1)	WO2003007991A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050113283A1 (en) *	2002-01-18	2005-05-26	David Solow-Cordero	Methods of treating conditions associated with an EDG-4 receptor
JPWO2004002530A1 (ja) *	2002-06-26	2005-10-27	小野薬品工業株式会社	慢性疾患治療剤
EP2565178A1 (de)	2002-10-03	2013-03-06	Ono Pharmaceutical Co., Ltd.	LPA-Rezeptorantagonisten
JP4692281B2 (ja) *	2003-08-05	2011-06-01	味の素株式会社	新規アゾール化合物
JP4779650B2 (ja) *	2003-12-26	2011-09-28	小野薬品工業株式会社	高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法
US20090068281A1 (en) *	2005-03-29	2009-03-12	Koji Toyomura	Composition, Functional Food and Pharmaceutical Composition for Improvement in Obesity
WO2009082491A1 (en) *	2007-12-26	2009-07-02	Alp Life Sciences, Llc	Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
US8802706B2 (en) *	2008-08-07	2014-08-12	Nagasaki University	Method for treating fibromyalgia
WO2010068775A2 (en)	2008-12-11	2010-06-17	Amira Pharmaceuticals, Inc.	Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) *	2008-12-15	2010-12-08	Amira Pharmaceuticals Inc	Antagonists of lysophosphatidic acid receptors
GB2470833B (en)	2009-06-03	2011-06-01	Amira Pharmaceuticals Inc	Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en)	2009-08-04	2011-02-10	Amira Pharmaceuticals, Inc.	Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en)	2009-10-01	2011-10-12	Amira Pharmaceuticals Inc	Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en)	2009-10-01	2011-12-21	Amira Pharmaceuticals Inc	Compounds as Lysophosphatidic acid receptor antagonists
JP2014513077A (ja)	2011-04-05	2014-05-29	アミラファーマシューティカルス，インコーポレーテッド	線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物
CA2844982A1 (en)	2011-08-15	2013-02-21	Intermune, Inc.	Lysophosphatidic acid receptor antagonists
JP6139781B2 (ja) *	2014-04-04	2017-05-31	国立大学法人大阪大学	リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999035259A1 (en) *	1997-12-30	1999-07-15	Nps Allelix Corp.	Identification of lysolipid receptors involved in inflammatory response
EP1364659A1 (de) *	2001-02-08	2003-11-26	Ono Pharmaceutical Co., Ltd.	Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6380177B1 (en) *	1999-06-25	2002-04-30	Atairgin Technologies, Inc.	LPA analogs as agonists of the Edg2 LPA receptor
AU2001232340A1 (en) *	2000-02-18	2001-08-27	Kirin Beer Kabushiki Kaisha	Novel isoxazole and thiazole compounds and use thereof as drugs
ATE380187T1 (de) *	2000-03-17	2007-12-15	Univ Tennessee Res Corp	Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden

2002
- 2002-07-16 US US10/483,815 patent/US20040171582A1/en not_active Abandoned
- 2002-07-16 JP JP2003513596A patent/JPWO2003007991A1/ja not_active Withdrawn
- 2002-07-16 EP EP02746091A patent/EP1415667B1/de not_active Expired - Lifetime
- 2002-07-16 AT AT02746091T patent/ATE406915T1/de not_active IP Right Cessation
- 2002-07-16 WO PCT/JP2002/007213 patent/WO2003007991A1/ja active IP Right Grant
- 2002-07-16 DE DE60228732T patent/DE60228732D1/de not_active Expired - Fee Related
- 2002-07-16 ES ES02746091T patent/ES2312588T3/es not_active Expired - Lifetime
2008
- 2008-04-30 US US12/112,538 patent/US20080234230A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999035259A1 (en) *	1997-12-30	1999-07-15	Nps Allelix Corp.	Identification of lysolipid receptors involved in inflammatory response
EP1364659A1 (de) *	2001-02-08	2003-11-26	Ono Pharmaceutical Co., Ltd.	Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Also Published As

Publication number	Publication date
WO2003007991A1 (fr)	2003-01-30
DE60228732D1 (de)	2008-10-16
JPWO2003007991A1 (ja)	2004-11-04
US20080234230A1 (en)	2008-09-25
ES2312588T3 (es)	2009-03-01
ATE406915T1 (de)	2008-09-15
US20040171582A1 (en)	2004-09-02
EP1415667B1 (de)	2008-09-03
EP1415667A1 (de)	2004-05-06

Legal Events

Date	Code	Title	Description
2004-03-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-05-06	17P	Request for examination filed	Effective date: 20040116
2004-05-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
2004-05-06	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-07-07	RIN1	Information on inventor provided before grant (corrected)	Inventor name: NAKADE, SHINJI,ONO PHARMACEUTICAL CO., LTD. Inventor name: SAGA, HIROSHI,ONO PHARMACEUTICAL CO., LTD.
2006-04-19	A4	Supplementary search report drawn up and despatched	Effective date: 20060306
2007-01-03	17Q	First examination report despatched	Effective date: 20061205
2007-11-13	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2008-04-03	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2008-08-01	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2008-09-03	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
2008-09-03	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2008-09-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2008-10-01	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2008-10-16	REF	Corresponds to:	Ref document number: 60228732 Country of ref document: DE Date of ref document: 20081016 Kind code of ref document: P
2009-01-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903
2009-02-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903
2009-03-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2312588 Country of ref document: ES Kind code of ref document: T3
2009-03-02	NLV1	Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
2009-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903
2009-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081203
2009-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090203 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903
2009-07-10	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2009-07-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2009-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903
2009-08-12	26N	No opposition filed	Effective date: 20090604
2010-01-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081203
2010-02-26	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731
2010-02-26	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2010-03-24	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20090716
2010-04-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20100331
2010-04-28	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2010-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731
2010-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090716
2010-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100202
2010-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090716
2010-09-28	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20090717
2010-10-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090717 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081204
2011-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090716
2011-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090716
2011-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903
2011-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080903

Publication	Publication Date	Title
EP1415667A4 (de)	2006-04-19	Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler
PT1474412E (pt)	2008-07-04	Produção do delta9-tetra-hidrocanabinol
MXPA02012273A (es)	2003-04-25	Antagonistas/agonistas inversos de glucagon.
Kokot et al.	1999	Effects of neuropeptide Y on appetite
AU6470090A (en)	1991-05-02	Substituted 5-((tetrazolyl)alkenyl)imidazoles
EP1758856A2 (de)	2007-03-07	Indolderivate zur behandlung von obesitas
HK1025315A1 (en)	2000-11-10	Imidazolyl-alkenoic acid
EP1416561A3 (de)	2005-04-06	Verfahren zum Betrieb eines Brennstoffzellensystems und Brennstoffzellensystem
MXPA04010625A (es)	2004-12-13	Antagonista de receptor de taquicinina.
UY26581A1 (es)	2001-09-28	Ligandos derivados de anilina para el receptor de la tiroides
AU3819497A (en)	1998-02-20	Novel parathyroid hormone-related peptide analogs
AU2023274183A1 (en)	2023-12-21	Compositions and methods for treatment of insulin resistance
UA49880C2 (uk)	2002-10-15	Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
MY129355A (en)	2007-03-30	Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
MXPA04005768A (es)	2004-09-10	Derivados de tetrahidrocarbazol como ligandos para receptores acoplados a proteina g (gpcr).
Hescheler et al.	1994	Heterotrimeric G proteins involved in the modulation of voltage-dependent calcium channels of neuroendocrine cells.
WO2003064452A3 (en)	2004-01-22	Method for the preparation of highly branched polypeptides
WO2004041208A3 (en)	2005-02-03	Controlled absorption of mixed thyroyd hormone formulations
UA77025C2 (en)	2006-10-16	Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
Crook et al.	1994	Stimulation of Na+, K+, Cl-cotransport by forskolin-activated adenylyl cyclase in fetal human nonpigmented epithelial cells.
EP1541171A4 (de)	2008-04-09	Mittel zur behandlung von diabetes mellitus
TWI256952B (en)	2006-06-21	Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
ES2194640T3 (es)	2003-12-01	Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion.
CN201759571U (zh)	2011-03-16	用于移动式c形臂x线机上的高压注射控制器
EP1077716A4 (de)	2003-03-19	Methode zur behandlung von refluxösophagitis